Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.

Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.

<h4>Background</h4>Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United...

Full description

Saved in:
Bibliographic Details
Main Authors: Abhishek Bhatia, Alexander J Preiss, Xuya Xiao, M Daniel Brannock, G Caleb Alexander, Robert F Chew, Hannah Davis, Megan Fitzgerald, Elaine Hill, Elizabeth P Kelly, Hemalkumar B Mehta, Charisse Madlock-Brown, Kenneth J Wilkins, Christopher G Chute, Melissa Haendel, Richard Moffitt, Emily R Pfaff, N3C Consortium
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1004493
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pmed.1004493

Similar Items